Century Therapeutics and FUJIFILM Cellular Dynamics Collaborate to Develop and Commercialize iPSC-Derived Cell Therapies to Treat Autoimmune and Inflammatory Diseases
Shots:
- Both companies have signed a new worldwide license agreement & has agreed to extend an existing license agreement for the development & commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases incl. type 1 diabetes, multiple sclerosis, lupus & rheumatoid arthritis. Moreover, a new agreement
- As per the agreement, FUJIFILM Cellular Dynamics will be eligible to receive certain development & regulatory milestone payments, plus royalties related to products developed under the collaboration
- Moreover, Century Therapeutics expects to report the results from the ongoing P-I (ELiPSE-1) clinical trial evaluating CNTY-101, an iPSC-derived CD19-specific CAR-NK cell therapy, in patients with r/r B cell lymphomas in ASH 2023 by YE 2023
Ref: Globenewswire | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
